Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine

Drugs and Aging

Volumn 21, Issue 6, 2004, Pages 395-403

  Suh, Dong Churl ^a   Arcona, Stephen ^b   Thomas, Simu K ^b   Powers, Christopher ^a   Rabinowicz, Adrian L ^b   Shin, Hyunchul ^a   Mirski, Dario ^b  

^a RUTGERS UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ZIPRASIDONE;

AGED; ALZHEIMER DISEASE; ARTICLE; CHI SQUARE TEST; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG EFFECT; DRUG SAFETY; DRUG USE; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RISK; STUDENT T TEST;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CARBAMATES; CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; PHENYLCARBAMATES; RISK ASSESSMENT; SEX CHARACTERISTICS;

EID: 2342472607     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421060-00004     Document Type: Article

References (43)

1. Yanker BA, Mesulam MM. Beta-amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med 1991; 325 (26): 1849-57
2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262 (18): 2551-6
3. Miech RA, Breitner JC, Zandi PP, et al. Incidence of AD may decline in the early 90s for men, later for women: The Cache County Study. Neurology 2002; 58 (2): 209-18
4. Minino AM, Arias E, Kochanek KD, et al. Deaths: final data for 2000. Natl Vital Stat Rep 2002; 50 (15): 1-120
5. Richards SS, Hendrie HC. Diagnosis, management, and treatment of Alzheimer's disease. Arch Intern Med 1999; 159: 789-98
6. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (7): 939-44
7. Highlights from the annual scientific assembly: managing the stages of Alzheimer's disease - new management options. South Med J 2002; 95 (1): 102-6
8. Levy ML, Cummings JL, Fairbanks LA, et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996; 153 (11): 1438-43
9. Coen RF, Swanwick GRJ, O'Boyle CA, et al. Behaviorial disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 331-6
10. Rymer S, Salloway S, Norton L, et al. Impaired awareness, behaviorial disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16 (4): 248-53
11. Robert P. Understanding and managing behavioral symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002; 18 (3): 156-77
12. Schneider LS. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry 1996; 57 Suppl. 14: 30-6
13. Krall WJ, Sramek JJ, Cutler NR, Cholinesterase inhibitors: a therapeutic strategy for Alzheimer's disease. Ann Pharmacother 1999; 33: 441-50
14. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's Disease. Ann N Y Acad Sci 2000; 920: 321-7
15. Barner EL, Gray SL. Donepezil use in Alzheimer's disease. Ann Pharmacother 1998; 32: 70-7
16. Huserau D, Wolfson C, Shukla V. Drug treatments for Alzheimer's disease: efficacy, outcome measurements and cost-effectiveness. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001 Jul. Technology Overview No. 4
17. National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine, and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence; 2001 Jan. Technology Appraisal Guidance No. 19
18. Raskind MA, Peskind ER. Alzheimer's disease and related disorders. Med Clin North Am 2001; 85 (3): 803-17
19. Lawlor B, Bhriain SN. Psychosis and behavioral symptoms of dementia: defining the role of neuroleptics. Int J Geriatr Psychiatry 2001; 16: S2-6
20. Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61 Suppl. 14: 49-52
21. Tariot PN. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996; 57 Suppl. 14: 21-9
22. Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56 (10): 1266-72
23. Rosler M, Retz W, Retz-Junginger P, et al. Effect of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer's disease. Behav Neurol 1998; 11 (4): 211-6
24. Inglis F, Sim A, Russell E. Behavioral benefits observed with rivastigmine in Alzheimer's disease [abstract]. Int Psychogeriatr 2001; 13 Suppl. 2: 236S
25. Mega MS, Masterman DM, O'Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56 (11): 1388-93
26. Bullock R, Moulais R, Steinwachs KC, et al. Effects of rivastigmine on behavioral symptoms in nursing home patients with Alzheimer's disease [abstract]. Int Psychogeriatr 2001; 13 Suppl. 2: 242S
27. Etemad B. Behavioral and cognitive benefits of rivastigmine in nursing home patients: a 26 week follow up [abstract]. Int Psychogeriatr 2001; 13 Suppl. 2: 241S
28. Cummings J, Anand R, Koumaras B, et al. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial. Neurology 2000; 54 Suppl. 3: A468-9
29. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheminer's disease therapy. Int Psychogeriatr 2002; 14 Suppl. 1: 77-91
30. Grossberg GT. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr 2002; 14 Suppl. 1: 27-49
31. Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56: 205-14
32. American Society of Health-System Pharmacists. American hospital formulary service drug information. Bethesda (MD): American Society of Health-System Pharmacists, 2002
33. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and troncated data. New York: Springer-Verlag Inc, 1997
34. Gambassi G, Landi F, Lapane KL, et al. Predictors of mortality in patients with Alzheimer's disease living in nursing homes. J Neurol Neurosurg Psychiatry 1999; 67: 59-65
35. Weiner M, Powe NR, Weller WE, et al. Alzheimer's disease under managed care: implications from Medicare utilization and expenditure patterns. J Am Geriatr Soc 1998; 46 (6): 762-70
36. Collett D. Modelling survival data in medical research. New York: Chapman & Hall, 1994
37. SAS Institute Inc. SAS/STAT user's guide. Version 8. Cary (NC): SAS Institute, 1999
38. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998; 20 (4): 838-50
39. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157 (1): 4-15
40. Cummings JL. Guidelines for managing Alzheimer's disease (Pt II): treatment Am Fam Physician 2002; 65 (12): 2525-34
41. Wennberg JE, Roos N, Sola L, et al. Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA 1987; 257 (7): 933-6
42. Newcomer R, Clay T, Luxenberg JS, et al. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records. J Am Geriatr Soc 1999; 47 (2): 215-9
43. Taylor DH, Fillenbaum GG, Ezell ME. The accuracy of medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol 2002; 55: 929-37